Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determine the Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants : the Clinical Analysis and Cell Lines Study

NCT04370860 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04370860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04370860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determine the Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants : the Clinical Analysis and Cell Lines Study
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Completed
Start date
May 1, 2020
Completion date
December 31, 2021
Enrollment
1,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 19 mutation, tumor progression